Day Two: Wednesday September 18, 2019
REGISTRATION & BREAKFAST
8:00
Introduction and Summary
8:30
Biomarkers & Companion Diagnostics
8:45
Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta
Vicki Plaks
Principal Scientist, CAR-T Cell Immunotherapy, Translational Medicine
Kite Pharma / Gilead
9:15
Translational Medicine Strategy in Acalabrutinib Clinical Development
Veerendra Munugalavadla
Director, Translational Medicine
Acerta Pharma / AstraZeneca
9:45
Next Gen. Sequencing for Next Gen. Drugs: MRD Assessment and Drug Development.
Philippe Nore
Vice President, Clinical Diagnostics
Adaptive Biotechnologies
MORNING REFRESHMENTS & NETWORKING
10:15
10:45
Measurable Residual Disease in Hematological malignancies:
Current State and Future Directions in Clinical Trial Implementation
Mark Stern
Director, Precision Medicine & CDx
Celgene
11:15
Revealing clonal selection and treatment resistance mechanisms in hematological malignancies with single-cell sequencing
Charlie Silver
CEO
Mission Bio
11:30
ONGOING RESULTS OF A PHASE 1B/2 DOSE-ESCALATION AND COHORT-EXPANSION STUDY OF THE SELECTIVE, NONCOVALENT, REVERSIBLE BRUTON’S TYROSINE KINASE INHIBITOR, VECABRUTINIB, IN B-CELL MALIGNANCIES
Pietro Taverna
Executive Director, Translational Medicine
Sunesis Pharmaceuticals
12:00
Applications of a custom-built ctDNA test to monitor treatment response in next-generation clinical trials
Alexey Aleshin
Medical Diretor, Oncology
Natera
LUNCH & NETWORKING
12:10
ROUNDTABLE DISCUSSIONS
1:00
Novel Approaches
2:00
SIFbodies: A Platform for Developing Superior Cell-Depleting Therapeutics
Amit Choudhury
Principal Scientist: Preclinical Pharmacology & Translational Medicine
Momenta Pharmaceuticals
2:30
Personalized Adoptive Cell Therapies: NeoAntigen-Targeted T Cells Against Cancer
Barbara Sennino
Associate Director, Tumor Immunology
PACT Pharma
3:00
A Novel T-Cell Engaging Bispecific Antibody Platform:
Maximizing Efficacy, Minimizing Toxicity
Kyle Lorentsen
Scientist I, Preclinical Development
Teneo Bio
3:30
Therapeutic Antibodies for Hematological Malignancies
Angus Sinclair
VP, Oncology
IGM Biosciences
SUMMARY & CLOSE OF CONFERENCE
4:00
VIEW PREVIOUS DAY
DOWNLOAD EVENT GUIDE
Complete the form below to download the PDF
NEO SYNTH Ltd. 8-13 St Pancras Way, London, NW1 0QG
contact@neo-synth.com
(+1) 617.500.5172
Your details will not be shared with a third party
CONNECT!
Follow Our Latest News on Twitter
Copyright © 2019 | All content produced by: Neo-Synth Ltd.